Enanta Pharmaceuticals (ENTA) Enterprise Value (2016 - 2025)
Enanta Pharmaceuticals (ENTA) has disclosed Enterprise Value for 14 consecutive years, with -$148.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 74.69% year-over-year to -$148.4 million, compared with a TTM value of -$729.5 million through Dec 2025, down 758.73%, and an annual FY2025 reading of -$156.6 million, up 36.92% over the prior year.
- Enterprise Value was -$148.4 million for Q4 2025 at Enanta Pharmaceuticals, up from -$156.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$85.0 million in Q4 2024 and bottomed at -$375.9 million in Q1 2021.
- Average Enterprise Value over 5 years is -$218.0 million, with a median of -$220.1 million recorded in 2023.
- Peak annual rise in Enterprise Value hit 74.8% in 2024, while the deepest fall reached 190.66% in 2024.
- Year by year, Enterprise Value stood at -$160.0 million in 2021, then dropped by 7.67% to -$172.2 million in 2022, then plummeted by 95.74% to -$337.2 million in 2023, then skyrocketed by 74.8% to -$85.0 million in 2024, then plummeted by 74.69% to -$148.4 million in 2025.
- Business Quant data shows Enterprise Value for ENTA at -$148.4 million in Q4 2025, -$156.6 million in Q3 2025, and -$204.1 million in Q2 2025.